U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 6 of 6 results

Status:
US Approved Rx (2002)
First approved in 1954

Class (Stereo):
CHEMICAL (ABSOLUTE)



Digoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Digoxin inhibits...
Gitoxigenin is a 16β-substituted digitoxigenin which may act as a Na+/K+-ATPase inhibitor. Cardiac glycosides (CGs), inhibitors of Na+/K+-ATPase (NKA), used clinically to treat heart failure, have garnered recent attention as potential anti-cancer an...
Status:
Other

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Digitoxigenin is a cardenolide and aglycone constituent of digitoxin, an extract from the foxglove plant, D. purpurea. It elicits cardiac contraction and cardiotonic effects by inhibiting the Na+/K+ ATPase via binding at the digitalis receptor site w...
Status:
US Previously Marketed
First approved in 1954

Class (Stereo):
CHEMICAL (ABSOLUTE)



Digoxin is a cardiac glycoside derived from the purple foxglove flower. In 1785, the English chemist, botanist, and physician Sir William Withering published his findings that Digitalis purpurea could be used to treat cardiac dropsy (congestive heart...
Status:
US Previously Marketed
First approved in 1954

Class (Stereo):
CHEMICAL (ABSOLUTE)



Digoxin is a cardiac glycoside derived from the purple foxglove flower. In 1785, the English chemist, botanist, and physician Sir William Withering published his findings that Digitalis purpurea could be used to treat cardiac dropsy (congestive heart...